Anti-HIV-1 activity of enfuvirtide (T-20) by inhibition of bystander cell death

Antiviral Therapy

Volumn 8, Issue 2, 2003, Pages 155-161

  Barretina, Jordi ^a   Blanco, Julià ^a   Armand Ugón, Mercedes ^a   Gutiérrez, Arantxa ^a   Clotet, Bonaventura ^a   Esté, José A ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ENFUVIRTIDE; GLYCOPROTEIN GP 120; MEMBRANE LIPID; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; BYSTANDER EFFECT; CELL DEATH; CELL FUSION; CELL INTERACTION; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS INHIBITION;

ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CELL DEATH; CELLS, CULTURED; COCULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; GIANT CELLS; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; PEPTIDE FRAGMENTS; VIRULENCE; VIRUS REPLICATION;

EID: 0037692990     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Berger EA, Murphy PM & Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annual Review of Immunology 1999; 17:657-700.
2. Chan DC & Kim PS. HIV entry and its inhibition. Cell 1998; 93:681-684.
3. Chan DC, Fass D, Berger JM & Kim PS. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997; 89:263-273.
4. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, Alldredge L, Hunter E, Lambert D, Bolognesi D, Matthews T, Johnson MR, Nowak MA, Shaw GM & Saag MS. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nature Medicine 1998; 4:1302-1307.
5. Badley AD, Pilon AA, Landay A & Lynch DH. Mechanisms of HIV-associated lymphocyte apoptosis. Blood 2000; 96:2951-2964.
6. Laurent-Crawford AG, Krust B, Riviere Y, Desgranges C, Muller S, Kieny MP, Dauguet C & Hovanessian AG. Membrane expression of HIV envelope glycoproteins triggers apoptosis in CD4 cells. AIDS Research & Human Retroviruses 1993; 9:761-773.
7. Blanco J, Jacotot E, Cabrera C, Cardona A, Clotet B, De Clercq E & Este JA. The implication of the chemokine receptor CXCR4 in HIV-1 envelope protein-induced apoptosis is independent of the G protein-mediated signalling. AIDS 1999; 13:909-917.
8. Blanco J, Barretina J, Henson G, Bridger G, De Clercq E, Clotet B & Este JA. The CXCR4 antagonist AMD3100 efficiently inhibits cell-surface-expressed human immunodeficiency virus type 1 envelope-induced apoptosis. Antimicrobial Agents & Chemotherapy 2000; 44:51-56.
9. Popovic M, Sarngadharan MG, Read E & Gallo RC. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 1984; 224:497-500.
10. Schwartz O, Alizon M, Heard JM & Danos O. Impairment of T cell receptor-dependent stimulation in CD4+ lymphocytes after contact with membrane-bound HIV-1 envelope glycoprotein. Virology 1994; 198:360-365.
11. Baba M, Miyake H, Okamoto M, Iizawa Y & Okonogi K. Establishment of a CCR5-expressing T-lymphoblastoid cell line highly susceptible to R5 HIV type 1. AIDS Research & Human Retroviruses 2000; 16:935-941.
12. Este JA, Schols D, De Vreese K, Van Laethem K, Vandamme AM, Desmyter J & De Clercq E. Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein. Molecular Pharmacology 1997; 52:98-104.
13. Este JA. HIV resistance to entry inhibitors. AIDS Reviews 2001; 1:121-132.
14. Rimsky LT, Shugars DC & Matthews TJ. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. Journal of Virology 1998; 72:986-993.
15. Kliger Y, Gallo SA, Peisajovich SG, Munoz-Barroso I, Avkin S, Blumenthal R & Shai Y. Mode of action of an antiviral peptide from HIV-1. Inhibition at a post lipid mixing stage. Journal of Biological Chemistry 2001; 276:1391-1397.
16. Eckert DM, Malashkevich VN, Hong LH, Carr PA & Kim PS. Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 1999; 99:103-115.
17. Berndt C, Mopps B, Angermuller S, Gierschik P & Krammer PH. CXCR4 and CD4 mediate a rapid CD95independent cell death in CD4(+) T cells. Proceedings of the National Academy of Sciences, USA 1998; 95:12556-12561.
18. Blanco J, Barretina J, Cabrera C, Gutierrez A, Clotet B & Este JA. CD4(+) and CD8(+) t cell death during human immunodeficiency virus infection in vitro. Virology 2001; 285:356-365.
19. Munoz-Barroso I, Durell S, Sakaguchi K, Appella E & Blumenthal R. Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41. Journal of Cell Biology 1998; 140:315-323.
20. Ferri KF, Jacotot E, Blanco J, Este JA, Zamzami N, Susin SA, Xie Z, Brothers G, Reed JC, Penninger JM & Kroemer G. Apoptosis control in syncytia induced by the HIV type 1-envelope glycoprotein complex. Role of mitochondria and caspases. Journal of Experimental Medicine 2000; 192:1081-1092.
21. Castedo M, Roumier T, Blanco J, Ferri KF, Barretina J, Tintignac LA, Andreau K, Perfettini JL, Amendola A, Nardacci R, Leduc P, Ingber DE, Druillennec S, Roques B, Leibovitch SA, Vilella-Bach M, Chen J, Este JA, Modjtahedi N, Piacentini M & Kroemer G. Sequential involvement of Cdk1, mTOR and p53 in apoptosis induced by the HIV-1 envelope. EMBO Journal 2002; 21:4070-4080.
22. Castedo M, Ferri KF, Blanco J, Roumier T, Larochette N, Barretina J, Amendola A, Nardacci R, Metivier D, Este JA, Piacentini M & Kroemer G. Human immunodeficiency virus 1 envelope glycoprotein complex-induced apoptosis involves mammalian target of rapamycin/FKBP12rapamycin-associated protein-mediated p53 phosphorylation. Journal of Experimental Medicine 2001; 194:1097-1110.
23. Stocker H, Scheller C & Jassoy C. Destruction of primary CD4(+) T cells by cell-cell interaction in human immunodeficiency virus type 1 infection in vitro. Journal of General Virology 2000; 81:1907-1911.
24. Lalezari J, Cohen C, Eron J, Kilby M, Nelson E & Sista P. Forty-eight week analysis of patients receiving T-20 as a component of multi-drug salvage therapy. XIII International AIDS Conference 2000; Durban, South Africa.
25. Miralles G, Demasi R, Sista P, Melby T, Duff F & Matthews T. Genotypic resistance to protease and reverse transcriptase inhibitors and antiretroviral history do not affect virologic response to T-1249. 41st Interscience Conference on Antimicrobial Agents & Chemotherapy. Chicago, Ill., USA (EEUU). December 16-19, 2001; Oral Presentation 1-669.
26. Tremblay CL, Kollmann C, Giguel F, Chou TC & Hirsch MS. Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100. Journal of Acquired Immune Deficiency Syndromes 2000; 25:99-102.
27. Nagashima KA, Thompson DA, Rosenfield SI, Maddon PJ, Dragic T & Olson WC. Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. Journal of Infectious Diseases 2001; 183:1121-1125.
28. Finkel TH, Tudor-Williams G, Banda NK, Cotton MF, Curiel T, Monks C, Baba TW, Ruprecht RM & Kupfer A. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nature Medicine 1995; 1:129-134.
29. Chinnaiyan AM, Woffendin C, Dixit VM & Nabel GJ. The inhibition of pro-apoptotic ICE-like proteases enhances HIV replication. Nature Medicine 1997; 3:333-337.
30. Mohri H, Perelson AS, Tung K, Ribeiro RM, Ramratnam B, Markowitz M, Kost R, Hurley A, Weinberger L, Cesar D, Hellerstein MK & Ho DD. Increased turnover of T lymphocytes in HIV-1 infection and its reduction by antiretroviral therapy. Journal of Experimental Medicine 2001; 194:1277-1287.
31. Kovacs JA, Lempicki RA, Sidorov IA, Adelsberger JW, Herpin B, Metcalf JA, Sereti I, Polis MA, Davey RT, Tavel J, Falloon J, Stevens R, Lambert L, Dewar R, Schwartzentruber DJ, Anver MR, Baseler MW, Masur H, Dimitrov DS & Lane HC. Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV. Journal of Experimental Medicine 2001; 194:1731-1741.
32. Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, Okamoto Y, Casazza JP, Kuruppu J, Kunstman K, Wolinsky S, Grossman Z, Dybul M, Oxenius A, Price DA, Connors M & Koup RA. HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002; 417:95-98.